Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Gynecol Oncol
    May 2023
  1. PRAISS AM, Miller A, Smith J, Lichtman SM, et al
    Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
    Gynecol Oncol. 2023;174:213-223.
    >> Share

  2. EURICH K, De La Cruz P, Laguna A, Woodman M, et al
    Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
    Gynecol Oncol. 2023;174:200-207.
    >> Share

  3. QIU Y, Zha J, Ma A, Zhou T, et al
    Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2023;174:175-181.
    >> Share

  4. FENG Z, Fu Y, Li R, Li H, et al
    Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
    Gynecol Oncol. 2023;174:142-147.
    >> Share

  5. WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
    The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
    Gynecol Oncol. 2023;174:121-128.
    >> Share

  6. NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
    Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
    Gynecol Oncol. 2023;173:138-150.
    >> Share

  7. ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
    Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
    Gynecol Oncol. 2023;174:89-97.
    >> Share

  8. SIA TY, Tew WP, Purdy C, Chi DS, et al
    The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
    Gynecol Oncol. 2023;173:130-137.
    >> Share

  9. BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
    Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
    Gynecol Oncol. 2023;172:106-114.
    >> Share

    April 2023
  10. PEREZ L, Webster E, Bull L, Brewer JT, et al
    Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
    Gynecol Oncol. 2023;173:106-113.
    >> Share

  11. GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
    PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
    Gynecol Oncol. 2023;173:98-105.
    >> Share

  12. CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
    Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
    Gynecol Oncol. 2023;173:31-40.
    >> Share

  13. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
    Gynecol Oncol. 2023;172:121-129.
    >> Share

  14. SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
    Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Gynecol Oncol. 2023;173:1-7.
    >> Share

    March 2023
  15. BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
    HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
    Gynecol Oncol. 2023;172:98-105.
    >> Share

  16. AREND R, Dholakia J, Castro C, Matulonis U, et al
    DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Gynecol Oncol. 2023;172:82-91.
    >> Share

  17. MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
    Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
    Gynecol Oncol. 2023;172:72-77.
    >> Share

  18. OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
    What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
    Gynecol Oncol. 2023;172:29-35.
    >> Share

  19. OSANN K, Wenzel L, McKinney C, Wagner L, et al
    Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
    Gynecol Oncol. 2023;171:151-158.
    >> Share

  20. BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
    A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2023;171:106-113.
    >> Share

  21. FOTOPOULOU C
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
    Gynecol Oncol. 2023;170:A1-A3.
    >> Share

  22. LEE SS, Karpel HC, Oh C, Smith J, et al
    Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Gynecol Oncol. 2023;170:234-240.
    >> Share

  23. LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
    Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
    Gynecol Oncol. 2023;170:93-101.
    >> Share

    February 2023
  24. HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
    The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;171:83-94.
    >> Share

  25. TANG H, Fayomi AP, Bai S, Gupta N, et al
    Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
    Gynecol Oncol. 2023;171:49-58.
    >> Share

  26. LI G, Xu W, Li X, Chen M, et al
    Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
    Gynecol Oncol. 2023;171:39-48.
    >> Share

  27. PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
    Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
    Gynecol Oncol. 2023;171:23-30.
    >> Share

  28. JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
    Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
    >> Share

  29. O'MALLEY DM, Ledermann JA, Coleman RL
    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
    Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
    >> Share

  30. HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
    Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:300-308.
    >> Share

  31. WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
    An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
    Gynecol Oncol. 2023;170:290-299.
    >> Share

  32. KOFOED NG, Falconer H, Vanky H, Johansson H, et al
    Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
    Gynecol Oncol. 2023;170:259-265.
    >> Share

  33. GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
    Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2023;170:241-247.
    >> Share

    January 2023
  34. DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
    Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2023;170:221-228.
    >> Share

  35. JAMIESON A, Singh N, Huvila J, Gilks CB, et al
    The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
    Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
    >> Share

  36. FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
    Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
    Gynecol Oncol. 2023;170:186-194.
    >> Share

  37. HAN C, McNamara B, Bellone S, Harold J, et al
    The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
    Gynecol Oncol. 2023;170:172-178.
    >> Share

  38. MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
    Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
    Gynecol Oncol. 2023;170:167-171.
    >> Share

  39. MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
    Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;170:133-142.
    >> Share

  40. NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
    Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2023;170:108-113.
    >> Share

  41. SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
    A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
    Gynecol Oncol. 2023;170:54-58.
    >> Share

  42. KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
    Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
    Gynecol Oncol. 2023;170:46-53.
    >> Share

  43. MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
    Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Gynecol Oncol. 2023;170:38-45.
    >> Share

  44. WANG DF, Shi XW, Zhang C, Zhang J, et al
    Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    Gynecol Oncol. 2023;170:25-31.
    >> Share

  45. KIM JH, Chun SY, Lee DE, Woo YH, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
    Gynecol Oncol. 2023;170:19-24.
    >> Share

  46. THOMSON CA, Crane TE, Miller A, Gold MA, et al
    Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2023;170:11-18.
    >> Share

    December 2022
  47. DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
    Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
    Gynecol Oncol. 2022;169:131-136.
    >> Share

  48. EHMANN S, Shay K, Zhou Q, Iasonos A, et al
    Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2022;169:118-124.
    >> Share

  49. ARMSTRONG DK
    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
    Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
    >> Share

  50. KAHN R, Filippova O, Gordhandas S, An A, et al
    Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
    Gynecol Oncol. 2022;169:85-90.
    >> Share

  51. WOOD N, Morton M, Shah SN, Yao M, et al
    Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2022;169:55-63.
    >> Share

  52. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2022;169:41-46.
    >> Share

  53. MATULONIS UA
    The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
    Gynecol Oncol. 2022;167:401-403.
    >> Share

    November 2022
  54. CRUM CP, Yoon JY, Feltmate CM
    Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
    Gynecol Oncol. 2022;169:1-3.
    >> Share

  55. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
    Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
    >> Share

  56. SHU T, Zhou Z, Bai J, Xiao X, et al
    Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2022;168:135-143.
    >> Share

  57. AKESSON A, Adok C, Dahm-Kahler P
    Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
    Gynecol Oncol. 2022;168:127-134.
    >> Share

  58. WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
    Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Gynecol Oncol. 2022;168:76-82.
    >> Share

  59. MARK J, Fisher DT, Kim M, Emmons T, et al
    Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
    Gynecol Oncol. 2022;168:92-99.
    >> Share

  60. YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
    Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    Gynecol Oncol. 2022;168:83-91.
    >> Share

  61. PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
    Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
    Gynecol Oncol. 2022;168:68-75.
    >> Share

  62. PIAO H, Wu M, Qin S, Tang Z, et al
    Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2022;168:17-22.
    >> Share

  63. MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
    Profiling the immune landscape in mucinous ovarian carcinoma.
    Gynecol Oncol. 2022;168:23-31.
    >> Share

  64. PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
    Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
    Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
    >> Share

  65. MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
    Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
    Gynecol Oncol. 2022;168:1-7.
    >> Share

  66. ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
    Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
    >> Share

    October 2022
  67. KIM SI, Kim JH, Lee S, Cho H, et al
    Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
    >> Share

  68. O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
    >> Share

  69. CHENG A, Rao Q, Liu Y, Huang C, et al
    Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
    >> Share

  70. EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
    DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
    >> Share

  71. FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
    A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
    >> Share

  72. CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
    The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
    >> Share

  73. GARZON S, Grassi T, Mariani A, Kollikonda S, et al
    Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
    >> Share

  74. ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
    Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
    Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
    >> Share

  75. LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
    Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
    >> Share

  76. POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
    Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
    >> Share

  77. VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
    Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
    Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
    >> Share

    September 2022
  78. KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
    A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
    >> Share

  79. YFAT K, Mariam K, Mario B, Hal H, et al
    Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
    >> Share

  80. WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
    Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
    >> Share

  81. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    >> Share

  82. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    >> Share

  83. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    >> Share

  84. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    >> Share

  85. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    >> Share

  86. LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
    OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
    Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
    >> Share

  87. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    >> Share

    August 2022
  88. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
    Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
    >> Share

  89. BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
    Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
    >> Share

  90. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    >> Share

  91. MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
    What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
    >> Share

  92. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    >> Share

  93. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    >> Share

    July 2022
  94. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    >> Share

  95. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    >> Share

  96. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    >> Share

  97. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    >> Share

  98. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    >> Share

  99. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    >> Share

  100. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    >> Share

  101. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    >> Share

  102. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    >> Share

  103. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    >> Share

  104. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    >> Share

  105. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    >> Share

    June 2022
  106. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    >> Share

  107. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    >> Share

  108. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    >> Share

  109. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    >> Share

  110. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    >> Share

  111. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    >> Share

  112. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    >> Share

  113. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    >> Share

  114. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    >> Share

  115. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    >> Share

    May 2022
  116. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    >> Share

  117. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    >> Share

  118. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    >> Share

  119. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    >> Share

  120. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    >> Share

  121. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    >> Share

    April 2022
  122. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    >> Share

  123. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    >> Share

  124. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    >> Share

  125. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    >> Share

  126. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    >> Share

  127. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    >> Share

  128. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    >> Share

  129. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    >> Share

  130. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    >> Share

    March 2022
  131. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    >> Share

  132. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    >> Share

  133. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    >> Share

  134. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    >> Share

  135. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    >> Share

  136. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    >> Share

  137. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    >> Share

  138. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    >> Share

  139. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    >> Share

    February 2022
  140. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    >> Share

  141. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    >> Share

  142. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    >> Share

  143. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    >> Share

  144. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    >> Share

  145. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    >> Share

  146. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    >> Share

  147. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    >> Share

  148. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    >> Share

  149. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    >> Share

  150. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    >> Share

  151. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    >> Share

    January 2022
  152. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    >> Share

  153. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    >> Share

  154. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    >> Share

  155. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    >> Share

  156. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    >> Share

  157. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    >> Share

  158. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    >> Share

  159. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    >> Share

  160. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    >> Share

  161. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    >> Share

  162. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    >> Share

    December 2021
  163. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    >> Share

  164. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    >> Share

  165. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    >> Share

  166. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    >> Share

  167. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    >> Share

  168. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    >> Share

  169. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    >> Share

  170. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    >> Share

  171. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    >> Share

  172. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    >> Share

  173. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    >> Share

  174. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    >> Share

  175. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    >> Share

    November 2021
  176. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    >> Share

  177. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    >> Share

  178. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    >> Share

  179. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    >> Share

  180. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    >> Share

  181. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    >> Share

  182. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    >> Share

  183. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    >> Share

  184. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    >> Share

  185. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    >> Share

  186. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    >> Share

    October 2021
  187. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    >> Share

  188. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    >> Share

  189. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    >> Share

  190. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    >> Share

  191. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    >> Share

  192. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    >> Share

  193. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    >> Share

  194. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    >> Share

  195. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    >> Share

  196. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    >> Share

  197. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    >> Share

  198. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    >> Share

  199. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    >> Share

  200. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    >> Share

  201. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    >> Share

  202. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    >> Share

  203. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    >> Share

    September 2021
  204. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    >> Share

  205. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    >> Share

  206. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    >> Share

  207. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    >> Share

  208. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    >> Share

  209. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    >> Share

  210. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    >> Share

  211. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    >> Share

  212. HUANG T, Townsend MK, Dood RL, Sood AK, et al
    Antihypertensive medication use and ovarian cancer survival.
    Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
    >> Share

  213. WENZEL L, Huang HQ, Cella D, McKinney CO, et al
    Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
    >> Share

  214. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    >> Share

  215. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    >> Share

  216. WANG Z, Guo E, Yang B, Xiao R, et al
    Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
    >> Share

  217. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    >> Share

  218. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    >> Share

    August 2021
  219. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    >> Share

  220. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    >> Share

  221. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    >> Share

  222. EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
    Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
    >> Share

  223. TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
    Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
    >> Share

  224. SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
    Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
    >> Share

  225. D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
    Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
    >> Share

  226. D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
    TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
    >> Share

  227. COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
    Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
    >> Share

  228. BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
    A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
    Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
    >> Share

  229. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    >> Share

  230. PARK M, Lim J, Lee JA, Park HJ, et al
    Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
    >> Share

  231. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    >> Share

  232. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    >> Share

  233. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    >> Share

  234. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    >> Share

  235. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    >> Share

    July 2021
  236. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    >> Share

  237. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    >> Share

  238. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    >> Share

  239. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    >> Share

  240. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    >> Share

  241. MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
    Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
    >> Share

  242. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    >> Share

  243. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    >> Share

  244. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    >> Share

  245. DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
    Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
    >> Share

  246. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    >> Share

  247. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    >> Share

  248. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    >> Share

  249. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    >> Share

  250. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    >> Share

  251. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    >> Share

  252. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    >> Share

  253. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    >> Share

  254. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    >> Share

  255. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    >> Share

  256. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    >> Share

  257. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    >> Share

  258. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    >> Share

  259. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    >> Share

    June 2021
  260. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    >> Share

  261. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    >> Share

  262. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    >> Share

  263. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    >> Share

  264. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    >> Share

  265. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    >> Share

  266. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    >> Share

  267. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    >> Share

  268. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    >> Share

  269. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    >> Share

  270. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    >> Share

  271. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    >> Share

  272. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    >> Share

  273. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    >> Share

  274. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    >> Share

    May 2021
  275. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    >> Share

  276. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    >> Share

  277. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    >> Share

  278. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    >> Share

  279. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    >> Share

  280. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    >> Share

  281. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    >> Share

  282. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    >> Share

  283. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    >> Share

  284. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    >> Share

  285. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    >> Share

  286. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    >> Share

  287. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    >> Share

  288. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    >> Share

  289. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    >> Share

    April 2021
  290. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    >> Share

  291. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    >> Share

  292. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    >> Share

  293. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    >> Share

  294. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    >> Share

  295. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    >> Share

  296. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    >> Share

  297. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    >> Share

  298. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    >> Share

  299. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    >> Share

  300. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    >> Share

  301. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    >> Share

  302. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    >> Share

  303. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    >> Share

  304. CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
    Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
    Gynecol Oncol. 2021;161:282-290.
    >> Share

  305. JOU J, Zimmer Z, Charo L, Yau C, et al
    HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Gynecol Oncol. 2021;161:25-33.
    >> Share

    March 2021
  306. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    >> Share

  307. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    >> Share

  308. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    >> Share

  309. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    >> Share

  310. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    >> Share

  311. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    >> Share

  312. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    >> Share

  313. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    >> Share

  314. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    >> Share

  315. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    >> Share

  316. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    >> Share

  317. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    >> Share

  318. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    >> Share

  319. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    >> Share

  320. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    >> Share

  321. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    >> Share

  322. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    >> Share

  323. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    >> Share

  324. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    >> Share

  325. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    >> Share

  326. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    >> Share

    February 2021
  327. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    >> Share

  328. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    >> Share

  329. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    >> Share

  330. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    >> Share

  331. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    >> Share

  332. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    >> Share

  333. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    >> Share

  334. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    >> Share

  335. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    >> Share

  336. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    >> Share

  337. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    >> Share

  338. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    >> Share

    January 2021
  339. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    >> Share

  340. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    >> Share

  341. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    >> Share

  342. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    >> Share

  343. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    >> Share

  344. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    >> Share

  345. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    >> Share

  346. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    >> Share

  347. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    >> Share

  348. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    >> Share

  349. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    >> Share

  350. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    >> Share

    December 2020
  351. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    >> Share

  352. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    >> Share

  353. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    >> Share

  354. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    >> Share

  355. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    >> Share

  356. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    >> Share

  357. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    >> Share

  358. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    >> Share

  359. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    >> Share

  360. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    >> Share

  361. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    >> Share

  362. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    >> Share

  363. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    >> Share

  364. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    >> Share

    November 2020
  365. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    >> Share

  366. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    >> Share

  367. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    >> Share

  368. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    >> Share

  369. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    >> Share

  370. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    >> Share

  371. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    >> Share

  372. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    >> Share

  373. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    >> Share

  374. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    >> Share

  375. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    >> Share

  376. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    >> Share

  377. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    >> Share

  378. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    >> Share

  379. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    >> Share

  380. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    >> Share

  381. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    >> Share

  382. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    >> Share

  383. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    >> Share

  384. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    >> Share

  385. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    >> Share

  386. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    >> Share

  387. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    >> Share

  388. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    >> Share

    October 2020
  389. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    >> Share

  390. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    >> Share

  391. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    >> Share

  392. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    >> Share

  393. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    >> Share

  394. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    >> Share

  395. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    >> Share

  396. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    >> Share

  397. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    >> Share

  398. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    >> Share

  399. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    >> Share

  400. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    >> Share

  401. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    >> Share

  402. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    >> Share

  403. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    >> Share

  404. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    >> Share

  405. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    >> Share

  406. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    >> Share

  407. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    >> Share

    September 2020
  408. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    >> Share

  409. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    >> Share

  410. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    >> Share

  411. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    >> Share

  412. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    >> Share

  413. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    >> Share

  414. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    >> Share

  415. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    >> Share

  416. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    >> Share

  417. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    >> Share

  418. WALLBILLICH JJ, Morris RT, Ali-Fehmi R
    Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
    >> Share

  419. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    >> Share

    August 2020
  420. SHEN L, Xie L, Li R, Shan B, et al
    A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
    >> Share

  421. BELL SG, Dalton L, McNeish BL, Fang F, et al
    Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
    >> Share

  422. BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
    Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
    Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
    >> Share

    July 2020
  423. COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
    The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
    >> Share

  424. BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
    Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
    >> Share

  425. COBB LP, Sun CC, Iyer R, Nick AM, et al
    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
    >> Share

  426. WEISS AS, Swisher E, Pennington KP, Radke M, et al
    Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
    >> Share

  427. MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
    Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
    >> Share

  428. PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
    Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
    >> Share

  429. BERNARD L, Boucher J, Helpman L
    Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
    >> Share

  430. DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
    Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
    >> Share

  431. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    >> Share

    June 2020
  432. SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
    Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
    >> Share

  433. MARIA S, Faron M, Maulard A, Pautier P, et al
    Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
    >> Share

  434. PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
    Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
    >> Share

  435. MORRISON A, Nasioudis D
    Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
    >> Share

  436. VENERIS JT, Mahajan P, Frazier AL
    Contemporary management of ovarian germ cell tumors and remaining controversies.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
    >> Share

  437. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    >> Share

  438. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    >> Share

    May 2020
  439. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    >> Share

  440. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    >> Share

    April 2020
  441. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    >> Share

  442. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    >> Share

  443. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    >> Share

  444. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    >> Share

    March 2020
  445. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    >> Share

  446. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    >> Share

  447. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    >> Share

  448. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    >> Share

  449. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    >> Share

    February 2020
  450. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    >> Share

  451. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    >> Share

  452. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    >> Share

  453. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    >> Share

  454. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    >> Share

  455. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    >> Share

    January 2020
  456. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    >> Share

  457. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    >> Share

  458. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    >> Share

  459. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    >> Share

  460. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    >> Share

  461. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    >> Share

  462. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    >> Share

  463. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    >> Share

  464. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    >> Share

    December 2019
  465. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    >> Share

  466. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016